Metformin induces muscle atrophy by transcriptional regulation of myostatin via HDAC6 and FoxO3a
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: Skeletal muscle atrophy is a severe condition that involves loss of muscle mass and quality. Drug intake can also cause muscle atrophy. Biguanide metformin is the first‐line and most widely prescribed anti‐diabetic drug for patients with type 2 diabetes. The molecular mechanism of metformin in muscle is unclear. Methods: Myostatin expression was investigated at the protein and transcript levels after metformin administration. To investigate the pathways associated with myostatin signalling, we used real‐time polymerase chain reaction, immunoblotting, luciferase assay, chromatin immunoprecipitation assay, co‐immunoprecipitation, immunofluorescence, primary culture, and confocal microscopy. Serum analysis, physical performance, and immunohistochemistry were performed using our in vivo model. Results: Metformin induced the expression of myostatin, a key molecule that regulates muscle volume and triggers the phosphorylation of AMPK. AMPK alpha2 knockdown in the background of metformin treatment reduced the myostatin expression of C2C12 myotubes (−49.86 ± 12.03%, P < 0.01) and resulted in increased myotube diameter compared with metformin (+46.62 ± 0.88%, P < 0.001). Metformin induced the interaction between AMPK and FoxO3a, a key transcription factor of myostatin. Metformin also altered the histone deacetylase activity in muscle cells (>3.12‐fold ± 0.13, P < 0.001). The interaction between HDAC6 and FoxO3a induced after metformin treatment. Confocal microscopy revealed that metformin increased the nuclear localization of FoxO3a (>3.3‐fold, P < 0.001). Chromatin immunoprecipitation revealed that metformin induced the binding of FoxO3a to the myostatin promoter. The transcript‐level expression of myostatin was higher in the gastrocnemius (GC) muscles of metformin‐treated wild‐type (WT) (+68.9 ± 10.01%, P < 0.001) and db/db mice (+55.84 ± 6.62%, P < 0.001) than that in the GC of controls (n = 4 per group). Average fibre cross‐sectional area data also showed that the metformin‐treated C57BL/6J (WT) (−31.74 ± 0.75%, P < 0.001) and C57BLKS/J‐db/db (−18.11 ± 0.94%, P < 0.001) mice had decreased fibre size of GC compared to the controls. The serum myoglobin level was significantly decreased in metformin‐treated WT mice (−66.6 ± 9.03%, P < 0.01). Conclusions: Our results demonstrate that metformin treatment impairs muscle function through the regulation of myostatin in skeletal muscle cells via AMPK‐FoxO3a‐HDAC6 axis. The muscle‐wasting effect of metformin is more evident in WT than in db/db mice, indicating that more complicated mechanisms may be involved in metformin‐mediated muscular dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms regulating skeletal muscle growth and atrophy
Schiaffino, S., Dyar, K. A., Ciciliot, S., Blaauw, B., & Sandri, M. (2013) · The FEBS Journal · doi:10.1111/febs.12253 · Cited by 1,492
Cellular and molecular mechanisms of muscle atrophy
Bonaldo, P., & Sandri, M. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.010389 · Cited by 1,284
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889 · cited 1×
“In vitro studies and in vivo used much higher doses of metformin than those clinical studies.(16,36,37) In the present study, we used 2 mM in vitro and 250 mg/kg in vivo.”
MethodSelf-citationWang, X., Hu, Z., Hu, J., Du, J., & Mitch, W. E. (2006) · Endocrinology · doi:10.1210/en.2006-0251 · Cited by 600
Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways
Rodriguez, J., Vernus, B., Chelh, I., Cassar-Malek, I., Gabillard, J. C., Hadj Sassi, A., Seiliez, I., Picard, B., & Bonnieu, A. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1689-x · Cited by 397
The Role of AMPK in the Regulation of Skeletal Muscle Size, Hypertrophy, and Regeneration
Thomson, D. M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103125 · Cited by 267
Walton, R. G., Dungan, C. M., Long, D. E., Tuggle, S. C., Kosmac, K., Peck, B. D., Bush, H. M., Villasante Tezanos, A. G., McGwin, G., Windham, S. T., et al. (2019) · Aging Cell · doi:10.1111/acel.13039 · Cited by 210 · cited 1×
“Because metformin reduces inflammation, the researcher of the study hypothesized that metformin would augment the muscle response; however, the placebo group had more gains in lean body and thigh muscle mass than the metformin-treated group.(33) Another study suggested that leg lean mass and appendicular skeletal musc…”
ResultLatres, E., Pangilinan, J., Miloscio, L., Bauerlein, R., Na, E., Potocky, T. B., Huang, Y., Eckersdorff, M., Rafique, A., Mastaitis, J., et al. (2015) · Skeletal Muscle · doi:10.1186/s13395-015-0060-8 · Cited by 143
Hall, D. T., Griss, T., Ma, J. F., Sanchez, B. J., Sadek, J., Tremblay, A. M. K., Mubaid, S., Omer, A., Ford, R. J., Bedard, N., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708307 · Cited by 88 · cited 1×
“prevents the progression of cytokine-induced myotube wasting.(34) On the other hand, our results support the negative effects of metformin on muscle hypertrophy.”
ResultMadsen, K. S., Chi, Y., Metzendorf, M.-I., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008558.pub2 · Cited by 70 · cited 1×
“hibits anabolic processes such as protein synthesis, enhances protein degradation and autophagy, and(12,13) decreases serum glucose levels.(14,15) Metformin administration”
Background
Cited by
Sarcopenic obesity: Emerging mechanisms and therapeutic potential
Axelrod, C. L., Dantas, W. S., & Kirwan, J. P. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155639 · Cited by 204
Prokopidis, K., Giannos, P., Reginster, J. Y., Bruyere, O., Petrovic, M., Cherubini, A., Triantafyllidis, K. K., Kechagias, K. S., Dionyssiotis, Y., Cesari, M., et al. (2023) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13190 · Cited by 51
Myostatin: a potential therapeutic target for metabolic syndrome
Yang, M., Liu, C., Jiang, N., Liu, Y., Luo, S., Li, C., Zhao, H., Han, Y., Chen, W., Li, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1181913 · Cited by 33
Metadata
- Authors
- Kang, M. J., Moon, J. W., Lee, J. O., Kim, J. H., Jung, E. J., Kim, S. J., Oh, J. Y., Wu, S. W., Lee, P. R., Park, S. H., & Kim, H. S.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2021-11-02
- Volume
- 13
- Issue
- 1
- Pages
- 605-620
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W3209174602
- Cited by
- 101
- References
- 10
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin induces muscle atrophy by transcriptional regulation of myostatin via HDAC6 and FoxO3a. https://app.cochat.ai/papers/10.1002/jcsm.12833
- The paper
- Kang, M. J., Moon, J. W., Lee, J. O., Kim, J. H., Jung, E. J., Kim, S. J., Oh, J. Y., Wu, S. W., Lee, P. R., Park, S. H., & Kim, H. S. (2022). Metformin induces muscle atrophy by transcriptional regulation of myostatin via HDAC6 and FoxO3a. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.12833
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.